Member Info for ciaskin

When SCIB1 was included to the standard of care regimen of ipilimumab with nivolumab, the overall size of metastatic melanoma lesions had reduced significantly in 9/11 patients,

yielding a RECIST 1.1 overall response rate of 82%. Due to the target of 9 responses being achieved earlier than expected, the study advanced to the second stage of Simon and non-futility was

declared. Of the two patients that did not achieve a RECIST 1.1 response, 1 patient had progressive disease within 7 weeks of entering the study and the other patient had a decrease of -24.1%

of their target lesions at 13 weeks (a RECIST 1.1 SD).

This patient is currently ongoing with their study treatment . In stage 2, an additional 18 responders are required in a maximum of 32 patients

but based on the current data the probability of success is expected to be ~90%. Cohort 2 is ongoing.

Thanks Berm - understood - and much appreciated!

No worries Berm. It was just an idle question as I don't know my way round that site, but as far as I can see, they update every Wednesday around 13.00 GMT? As today's publications seemed to relate to patents lodged up to 14th September, I was surmising whether SCLP's latest ( lodged on 17/9) is likely to appear in full next week?

Thanks Berm. I see that those published today were lodged on Sept 14th so is it likely that Scancell's (lodged on Sep 17th) will be published in next Wednesday's batch?

Morning Bankfool.

In answer to your question about how companies that don't make a profit are valued, AZs investment in Cellectis today may give some clues. (Cellectis is a US stock with shares trading yesterday at around $0.97 and a market cap of $54m):

In Q4 2023, Cellectis will receive an initial payment of $105m from AstraZeneca, which comprises a $25m upfront cash payment under the terms of a research collaboration agreement and an $80m equity investment.

The initial equity investment of $80m, at $5/share, represents an equity stake of c. 22% in Cellectis. A further $140m equity investment, at $5/share, is expected to close in early 2024 subject to the signing of a final binding agreement following completion of a consultation with the Cellectis employee representative bodies and customary closing conditions including Cellectis shareholders' approval and regulatory clearances. Post-closing of this second investment, AstraZeneca will hold a total equity stake of c. 44% in Cellectis. AstraZeneca expects to treat its investment in Cellectis as an associate.

Under the terms of the research collaboration, Cellectis is also eligible to receive an investigational new drug (IND) option fee and development, regulatory and sales-related milestone payments, ranging from $70m up to $220m, per each of the 10 candidate products, plus tiered royalties.

Abstract number 1533

Session date and time Friday, Nov. 3, 2023, 9am - 7pm EDT

Location Exhibit Halls A and B1 - San Diego Convention Center

A copy of the poster will be available on Scancell's website following the conference at: https://www.scancell.co.uk/vaccine-publications

We are pleased that our recently announced positive data from the first stage of our Phase 2 SCOPE trial has been selected for poster presentation at SITC. Better treatment outcomes are needed for patients with advanced melanoma and these highly impressive early results for SCIB1 combined with doublet CPI therapy demonstrate a meaningful improvement. The SCOPE trial is on track to complete recruitment by the end of 2023 with data available in H1 2024. We look forward to sharing more on these encouraging results at SITC and how this could make a significant impact on melanoma patient survival."

Hi Mayo.

I think you are mixing two different factors (Cash Balance and Operating Loss) which may be confusing things. If we just look at Cash Balance, that was £28.7m at end of April 2022 dropping to £19.9m at end of April 23. This would suggest an annual cash burn of £8.8m but there is of course the £5.3m Genmab upfront payment during the period too, making it a total annual cash burn of £14.1m - or £1.175m per month. Looking ahead - and with Covidity now on the shelf - I would expect the monthly burn to drop closer to £1m. So if we had £19.9m in cash at April 30th, that's effectively 20 months which would see us right through next year and (just) into 2025. This is a prudent forecast though, as it doesn't take into account any additional deals or other 'left field' events.

AIMHO - and good luck all!

I think it's a typo, Burble, and should read 2039. This is taken from the July update RNS:

"iSCIB1+ has a number of competitive advantages, with potentially increased potency due to modifications to the product using Scancell's propriety AvidiMab® platform, and an extended patent life to 2039. iSCIB1+ is able to be used by a broader patient population because it incorporates more melanoma-specific epitopes."

It looks like audit delays are pretty common and UNLESS there are material difficulties, an initial dip is followed by a bounce:

"Halfords shares dropped 7% yesterday to 185p following the notice but bumped back up to 195p this afternoon"

BDO has form on this...and more than once...

https://www.cityam.com/tetrosyl-seeks-1m-in-compensation-from-bdo-over-9-month-audit-delay/

https://www.retailgazette.co.uk/blog/2023/06/halfords-auditor-extends/

https://viconsortium.com/vi-business/virgin-islands-audit-delays-frustrate-matching-fund-special-purpose-board-as-bdo-falls-behind

Roll on 24th indeed - with just the small matter of Lindy speaking at the World Vaccine Congress on the 19th in the meantime...!

Hi Berm. I can't be entirely sure but I seem to recall that SCLP's attendance at ESMO was discussed either here or in the other place?

Hi WTP.

In the immediate future, it's the World Vaccine Congress in Barcelona (16th - 19th October) then a short hop to Madrid for ESMO (20th - 24th). Then back to Blighty for the Investors presentations on 24th.

Looks almost planned...!

Opens today in Barcelona. Lindy speaking on Thursday.

https://www.terrapinn.com/conference/world-vaccine-congress-europe/speaker-lindy-DURRANT.stm

Good luck Lindy - and good luck all!

Look what can happen when the right results drop...!

https://fortune.com/2023/10/13/tempest-therapeutics-shares-surge-after-roche-led-cancer-treatment-trial/

Scancell at ESMO Madrid (20th - 24th October). New analyst and investor meeting on 24th October. Hmmm....

16th - 20th October

So that potentially pivotal time in Spain is just 12 trading days away. Not long to go now...

Hi Berm.

Just to add, for everyone's reference, that the dates for the World Vaccine Congress are 16th-19th October in Barcelona, followed directly by ESMO in Madrid from 20th-24th.